EP0351410A1 - Peptide de liaison de complement - Google Patents

Peptide de liaison de complement

Info

Publication number
EP0351410A1
EP0351410A1 EP19880902527 EP88902527A EP0351410A1 EP 0351410 A1 EP0351410 A1 EP 0351410A1 EP 19880902527 EP19880902527 EP 19880902527 EP 88902527 A EP88902527 A EP 88902527A EP 0351410 A1 EP0351410 A1 EP 0351410A1
Authority
EP
European Patent Office
Prior art keywords
amino acid
polypeptide
sequence
lys
tail
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP19880902527
Other languages
German (de)
English (en)
Inventor
Gregory Paul Winter
Alexander Robert Duncan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
3I Research Exploitation Ltd
Original Assignee
Research Corp Ltd
3I Research Exploitation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB878706425A external-priority patent/GB8706425D0/en
Priority claimed from GB878718897A external-priority patent/GB8718897D0/en
Application filed by Research Corp Ltd, 3I Research Exploitation Ltd filed Critical Research Corp Ltd
Publication of EP0351410A1 publication Critical patent/EP0351410A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies

Definitions

  • This invention relates to a complement binding peptide and to pharmaceutical preparations containing sam
  • immunoglobulins particularly IgG and IgM, are able to bind the first component of complement, generally designated Cl.
  • Complement comprises a number of protein molecules which are sequentially activated by the binding of Cl to an Ig. Activation of complement is important in the opsonisation and lysis of cell pathogens. The activatio of complement also stimulates the inflammatory response and may be involved in autoimmune hypersensitivity.
  • the first component of complement, Cl comprises three proteins which bind tightly together. These proteins are Clq, Clr and Cls. It has been shown that Clq is responsible for binding the three protein complex to the Ig.
  • Ig's have two heavy chains linked together with disulphide bonds and two light chains, one light chain being linked to each of the heavy chains by disulphide bonds.
  • the general molecular structure of an Ig is show in Figure 1 of the accompanying drawings.
  • Each heavy chain has at one end a variable domain followed by a number of constant domains.
  • Each light chain has a variable domain at one end and a constant domain at its other end, the variable domain of the light chains being aligned with the variable domain of the heavy chain and the constant domain of each light chain is aligned with the first constant domain of the heavy chain.
  • the variable domains of each pair of light and heavy chains form an antigen binding site.
  • the portions of the heavy chains extending beyond the ends of the light chains can be separated from the remainder of the Ig by enzymatic cleavage to yield a fragment, known as the Fc fragment. It is known that the Fc fragment inhibits the interaction of Clq with an Ig.
  • the constant region of an Ig comprises at least two constant domains, CH2 and CH3, as- shown in Figure 1. . It is possible to cleave the CH3 domain from the rest of the Ig molecule. It has been shown that removal of the CH3 domain from an Ig does not remove its ability to bind Clq.
  • the binding site on the Ig for Clq is located within the CH2 domain.
  • synthetic peptides corresponding in sequence to short sections of the CH2 domain were tested for inhibition of binding. This work identified two possible binding sites.
  • a comparison of the sequences of CH2 domains of several Ig's was made in conjunction with studies of their three-dimensional structure. This lead to the identification of two further proposals for the site of binding Clq.
  • An object of the present invention is to provide a peptide binding to the Clq protein of complement.
  • polypeptide having the ability to inhibit complement mediated lysis, consisting of or containing the amino aci sequence I;
  • X is a polar amino acid
  • A is any amino acid; Y is a basic amino acid; ' and, Z is a basic amino acid
  • polypeptide having the ability to inhibit complement mediated lysis, having the general formula II:
  • X is, Asn, Glu, Thr or Gin
  • Y and Z are, independently, Lys, or Arg; • Head' is a hydrogen atom or a sequence of amino acid residues attached to the amino group of the adjacent amino acid X; 'Tail' is a hydrogen atom or a sequence of amino acid residues attached to the carboxyl group of the adjacent amino acid Y; and, each of the groups represented by A, which may be the same or different, is an amino acid residue.
  • the group X is Glu or Thr, and Y and Z are both Lys or Arg.
  • each A is a non-ionic, preferably polar, most preferably small, amino acid residue.
  • the groups represented by 'Head* and 'Tail' may be joined by a peptide bridge to form a cyclic polypeptide or an analogue.
  • the polypeptide may be a pentapeptide ('Head' and 'Tail' both being hydrogen atoms) or a longer peptide, for example a sequence of amino acids mimicing the natural sequence- of a complete or incomplete CH2 domain of an Ig.
  • 'Head' and 'Tail' comprise identical sequences of amino acids.
  • polypeptide of the invention has the sequence:
  • the polypeptide may be arranged so that side chains of the residues X Y and Z adopt approximately the configuration which they adopt in the CH2 domain of an Ig. This may be achieved by locating a polypeptide in a 'Head' and 'Tail' which together form a B-pleated sheet. Alternatively, this may be achieved by fixing the polypeptide to a carrier so that the polypeptide adopts a B-sheet-like configuration.
  • polypeptide analogue for instance an extended chain having appropriate functional groups attached thereto, it is only necessary to ensure that the functional groups are arranged in the same configuration as are the equivalent residues in the polypeptide.
  • the polypeptide analogue may compris an anti-peptide or anti-analogue, having the sequence Y-X-Z-X-z or Z-X-Z-X-Y, depending on being parellel or anti-parallel to the Clq binding sites of complement, wherein Y is a hydrogen bonding residue, each Z is independently a negatively charged residue and each X is independently an amino acid residue.
  • Such an anti-peptide would act by masking the necessary residues on an antibody structure, so that Clq would not be bound.
  • such an anti-peptide would be produced in two copies connected via a long flexible linker. Each copy in the long molecule would then bind to a respective CH2 domain in a single antibody molecule, thereby inhibiting Clq binding.
  • the polypeptide or its analogue of the present invention may be fixed on to a carrier, such as a protein polysaccharide or plastics material, or may be used as formed.
  • the polypeptide of the present invention may find application in the therapy of autoimmune diseases, such a lupus erythematosus, which are believed to be caused by non-specific or uncontrolled activation of Clq.
  • a polypeptide was synthesised, using standard laboratory techniques for polypeptide synthesis, having the following structure: Acetyl-Ala-Glu-Ala-Lys-Ala-Lys-Ala-Amide
  • the present invention has shown that it is possible to synthesise a polypeptide based on the sequence of the Glu318 to Lys322 sequence which can be used directly in, vivo to compete with the binding of Clq. This ability would be expected to have potential as an anti-infammatory drug.
  • FIG. 2 there is shown graphically the inhibition of complement lysis by synthetic peptides of this invention.
  • the circles represent lysis for the peptide Acetyl-Ala-Glu-Ala-Lys-Ala-Lys-Ala-NH- and squares indicate that same for a control ppeptide of sequence Ser-Asp-Glu-Lys-Ala-Ser-Pro-Asp-Lys-Tyr, which both contain acidic and basic residues.
  • Figure 2 was as follows: Peptides were purified by reverse-phase HPLC and the composition checked by amino acid analysis. Freeze dried peptide was weighed and dissolved in CFD (Complement Fixation Diluent - Oxoid) to a concentration of 4mM and serial dilutions of the peptide made into 200 microlitre NIP-derivatized red cells (5 x 7 10 cells/ml), guinea pig serum (1/40 dilution) and antibody (7 microgram/ml), and incubated at 37°C for 30 minutes and then scanned using a Titertek Multiscan (Trade

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Un polypeptide, ayant la capacité d'empêcher une lyse par complément, est constitué par ou contient la séquence d'acide aminé suivante (I): -X-A-Y-A-Z-, où X représente un acide aminé polaire; A représente n'importe quel acide aminé; Y représente un acide aminé basique; et Z représente un acide aminé basique. Dans un mode de réalisation préféré, le polypeptide est représenté par la formule générale (II): tête-X-A-Y-A-Z-queue; où X représente Asn, Glu, Thr ou Gln; Y et Z représentent séparément Lys ou Arg; la tête est constituée par un atome d'hydrogène ou par une séquence de résidus d'acides aminés fixés au groupe amino de l'acide aminé adjacent X; la queue est constituée par un atome d'hydrogène ou par une séquence de résidus aminés fixés au groupe carboxyle de l'acide aminé adjacent Y; et chacun des groupes représentés par A, qui peuvent être identiques ou différents, représente un résidu d'acide aminé.
EP19880902527 1987-03-18 1988-03-18 Peptide de liaison de complement Withdrawn EP0351410A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB8706425 1987-03-18
GB878706425A GB8706425D0 (en) 1987-03-18 1987-03-18 Altering complement activity of antibodies
GB8718897 1987-08-10
GB878718897A GB8718897D0 (en) 1987-08-10 1987-08-10 Altering complement binding activity of antibodies

Publications (1)

Publication Number Publication Date
EP0351410A1 true EP0351410A1 (fr) 1990-01-24

Family

ID=26292028

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19880902527 Withdrawn EP0351410A1 (fr) 1987-03-18 1988-03-18 Peptide de liaison de complement

Country Status (2)

Country Link
EP (1) EP0351410A1 (fr)
WO (1) WO1988007054A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7053202B2 (en) 2001-10-19 2006-05-30 Millennium Pharmaceuticals, Inc. Immunoglobulin DNA cassette molecules, monobody constructs, methods of production, and methods of use therefor
PT2697257T (pt) 2011-04-13 2016-12-28 Bristol Myers Squibb Co Proteínas de fusão fc compreendendo novos ligantes ou arranjos
NZ721184A (en) 2011-09-30 2018-08-31 Dana Farber Cancer Inst Inc Therapeutic peptides
US10065987B2 (en) 2013-02-12 2018-09-04 Bristol-Myers Squibb Company High pH protein refolding methods
WO2014126871A1 (fr) 2013-02-12 2014-08-21 Bristol-Myers Squibb Company Procédés de repliement de protéine utilisant la filtration tangentielle
US9546203B2 (en) 2013-03-14 2017-01-17 Amgen Inc. Aglycosylated Fc-containing polypeptides with cysteine substitutions
EP2970908B1 (fr) 2013-03-15 2019-12-25 Dana-Farber Cancer Institute, Inc. Peptides thérapeutiques
ES2755129T3 (es) 2013-12-06 2020-04-21 Dana Farber Cancer Inst Inc Péptidos terapéuticos
WO2015139020A2 (fr) 2014-03-14 2015-09-17 Dana-Farber Cancer Institute, Inc. Compositions vaccinales et méthodes pour rétablir la fonction de la voie nkg2d contre les cancers
UA126270C2 (uk) 2015-04-10 2022-09-14 Емджен Інк. Мутеїни інтерлейкіну-2 для росту регуляторних t-клітин
US11634495B2 (en) 2017-04-07 2023-04-25 Miltenyi Biotec B.V. & Co. KG Methods of activating CD32b/c comprising administering an antibody that binds BDCA-2 (CD303)

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO8807054A1 *

Also Published As

Publication number Publication date
WO1988007054A1 (fr) 1988-09-22

Similar Documents

Publication Publication Date Title
Liu et al. New procedures for preparation and isolation of conjugates of proteins and a synthetic copolymer of D-amino acids and immunochemical characterization of such conjugates
Cunningham et al. Complete amino acid sequence of β2-microglobulin
Hodges et al. Antigen-antibody interaction. Synthetic peptides define linear antigenic determinants recognized by monoclonal antibodies directed to the cytoplasmic carboxyl terminus of rhodopsin.
Gleich et al. Biochemical and functional similarities between human eosinophil-derived neurotoxin and eosinophil cationic protein: homology with ribonuclease.
Deuel et al. Amino acid sequence of human platelet factor 4.
Südhof et al. Cassette of eight exons shared by genes for LDL receptor and EGF precursor
Lukas et al. Inhibition of C1-mediated immune hemolysis by monomeric and dimeric peptides from the second constant domain of human immunoglobulin G.
Kunihiko et al. A second class of immunoglobulin other than IgM present in the serum of a cartilaginous fish, the skate, Raja kenojei: isolation and characterization
US4220565A (en) Immunochemical conjugates: method and composition
Sharon et al. Possible association between IL-2 receptors and class I HLA molecules on T cells.
Stauber et al. The γ‐aminobutyric‐acid/benzodiazepine‐receptor protein from rat brain: Large‐scale purification and preparation of antibodies
Hannestad et al. Polyclonal human antibodies to IgG (rheumatoid factors) which cross‐react with cell nuclei
Mole et al. The isolation and characterization of the VH domain from rabbit heavy chains of different a locus allotype
Barakat et al. IgG antibodies from patients with primary Sjögren's syndrome and systemic lupus erythematosus recognize different epitopes in 60‐kD SSA/Ro protein
EP0351410A1 (fr) Peptide de liaison de complement
Gergely et al. Chemical Analyses of Variable Regions of Heavy and Light Chains of Cold Agglutinins 1
Takano et al. Purification and biochemical characterization of nuclear ribonucleoprotein antigen using purified antibody from serum of a patient with mixed connective tissue disease
US4276206A (en) Immunochemical conjugates: method and composition
US5578496A (en) Detection of autoantibodies associated with the disease myasthenia gravis
US4253996A (en) Immunochemical conjugates: method and composition
Elsayed et al. Epitope mapping of region 11–70 of ovalbumin (Gal d I) using five synthetic peptides
Jouault et al. Quantitative and qualitative analysis of the Fc receptor for IgE (FcεRII) on human eosinophils
Milstein et al. Disulphide bridges of the heavy chain of human immunoglobulin G2
KR960701201A (ko) 뼈의 촉진인자(bone stimulating factor)
US4253995A (en) Immunochemical conjugates: method and composition

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19890918

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): DE FR GB IT

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: 3I RESEARCH EXPLOITATION LIMITED

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Withdrawal date: 19910625

R18W Application withdrawn (corrected)

Effective date: 19910625